L'Institut Pasteur (The Pasteur Institute) is a non-profit private research institution founded by Louis Pasteur on 4 June 1887 in Paris, France. The Institute's research focuses on the study of infectious diseases, micro-organisms, viruses, and vaccines. As of 2014, ten scientists have received Nobel Prizes in physiology or medicine for the research they have done at the Pasteur Institute. Contrary to the way genetics was studied in US research universities during the mid-twentieth century, the genetic research conducted at the Pasteur Institute at the same time did not rest on a conceptual separation between embryology and evolution. According to historian Michel Morange from the Ecole Normale Superieure in Paris, France, this difference enabled Pasteurian scientists to develop the concepts of regulatory genes and of developmental genes.

In 2011, Inga Kristen, Julius Sewangi, Andrea Kunz, Festo Dugange, Judith Ziske, Brigitte Jordan-Harder, Gundel Harms, and Stefanie Theuring published the article, “Adherence to Combination Prophylaxis for Prevention of Mother-to-Child-Transmission of HIV in Tanzania,” in PLoS ONE. Hereafter, “Adherence to Combination Prophylaxis,” the article details the authors’ investigation into the efficacy of a medication regimen called combination prophylaxis to prevent mother-to-child, or MTC, transmission of Human Immunodeficiency Virus, or HIV, before, during, and after delivery. They included pregnant women who had HIV, in Kyela, Tanzania. However, through interviews and surveys, the authors found that many women had difficulty adhering to the regimen, which made the medication less effective. Kristen and colleagues suggest that healthcare professionals who treat HIV-positive pregnant women increase hospital resources and prescribe medication to those women early in the pregnancy to reduce MTC transmission of HIV.

To address the international Human Immunodeficiency Virus epidemic, the World Health Organization, or WHO, developed three drug treatment regimens between 2010 and 2012 specifically for HIV-positive pregnant women and their infants. WHO developed the regimens, calling them Option A, Option B, and Option B+, to reduce or prevent mother-to-child, abbreviated MTC, transmission of HIV. Each option comprises of different types and schedules of antiretroviral medications. As of 2018, WHO reported that in Africa alone about 1,200,000 pregnant women were living with untreated HIV. Those women have up to a forty-five percent chance of transmitting HIV to their offspring if they do not receive treatment. Option B+ has decreased the overall maternal mortality rates in many low- and middle-income countries, and numerous studies have supported the notion that it is the most effective of the three regimens for preventing MTC transmission of HIV.

In 2018, researchers Elie Nkwabong, Romuald Meboulou Nguel, Nelly Kamgaing, and Anne Sylvie Keddi Jippe published, “Knowledge, Attitudes, and Practices of Health Personnel of Maternities in the Prevention of Mother-To-Child Transmission of HIV in a sub-Saharan African Region with High Transmission Rate: Some Solutions Proposed,” in BMC Pregnancy and Childbirth. In their article, hereafter “Knowledge, Attitudes, and Practices,” the authors state the aim of their study was to establish the knowledge, attitudes, and practices held by health professionals who worked in numerous maternal departments throughout Cameroon. They claimed that effective knowledge, attitudes, and practices would likely reduce mother-to-child, hereafter MTC, transmission of HIV. After finding a deficit in the knowledge, attitudes, and practices among a subset of health professionals, the authors recommended increased training, funding, and supervision to reduce MTC transmission of HIV throughout Cameroon.

Luc Montagnier studied viruses, the immune system, and cancer in France during the second half of the twentieth century. In his early career, Montagnier studied how cancer-causing viruses replicate and infect host cells. He received the Nobel Prize in Physiology or Medicine in 2008 for his team’s discovery that a retrovirus, human immunodeficiency virus, or HIV, was the cause of acquired immunodeficiency syndrome, or AIDS. AIDS is a chronic condition that results from HIV infection and damages the immune system. People who have AIDS typically experience increased vulnerability to a variety of diseases. Before Montagnier’s research on the virus, the exact cause of AIDS remained unknown to researchers and healthcare professionals. Beyond discovering HIV as the cause of AIDS, Montagnier’s work advanced a general understanding of how viral infection affects the immune system of the host organism.

To address the international Human Immunodeficiency Virus epidemic, the World Health Organization, or WHO, developed three drug treatment regimens between 2010 and 2012 specifically for HIV-positive pregnant women and their infants. WHO developed the regimens, calling them Option A, Option B, and Option B+, to reduce or prevent mother-to-child, abbreviated MTC, transmission of HIV. Each option comprises of different types and schedules of antiretroviral medications. As of 2018, WHO reported that in Africa alone about 1,200,000 pregnant women were living with untreated HIV. Those women have up to a forty-five percent chance of transmitting HIV to their offspring if they do not receive treatment. Option B+ has decreased the overall maternal mortality rates in many low- and middle-income countries, and numerous studies have supported the notion that it is the most effective of the three regimens for preventing MTC transmission of HIV.

Ian Hector Frazer studied the human immune system and vaccines in Brisbane, Australia, and helped invent and patent the scientific process and technology behind what later became the human papillomavirus, or HPV, vaccinations. According to the Centers for Disease Control and Prevention of the US, or CDC, HPV is the most common sexually transmitted infection, and can lead to genital warts, as well as cervical, head, mouth, and neck cancers. Frazer and virologist Jian Zhou conducted research in the 1990s to assess why women with HPV had higher rates of precancerous and cancerous cervical cells. Frazer’s research led the pharmaceutical company Merck to produce the Gardasil vaccination series, and GlaxoSmithKline to produce the Cervarix vaccination. Frazer’s research contributed to the development of HPV vaccinations that have been successful in reducing up to seventy percent of cervical cancer cases in women.

Gertrude Belle Elion was a twentieth-century scientist in the US who researched the structure of viral DNA to help develop anti-viral medications. For her work on drug development, Elion was a co-recipient of the 1988 Nobel Prize in Physiology or Medicine, even though she lacked a PhD or MD. In the 1970s, Elion helped to develop acyclovir, an early anti-viral medication, alongside a team of other researchers. Acyclovir was one of the first selective medications to effectively treat herpes simplex virus types 1 and 2, or HSV-1 and HSV-2. Those are common viruses that can be transmitted via close contact or sexual intercourse, and cause sores on the mouth and genitals. The medications that Elion helped develop were also some of the first to specifically inhibit the replication of viral DNA. By creating medications like acyclovir based on her knowledge of chemistry and biology, rather than through trial and error, Elion helped create a new model for drug development, in addition to making an effective treatment for herpes, which afflicts billions of people globally, and can cause life-threatening illness in infants.